Open AccessAccumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda
Author(s) -
Emmanuel Ndashimye,
Mariano Avino,
Abayomi S Olabode,
Art F. Y. Poon,
Richard Gibson,
Yue Li,
Adam Meadows,
Christine Tan,
Paul S Reyes,
Cissy Kityo,
Fred Kyeyune,
Immaculate Nankya,
Miguel E. QuiñonesMateu,
Jos Arts
Publication year - 2020
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa355
Subject(s) - raltegravir , elvitegravir , dolutegravir , integrase , virology , integrase inhibitor , biology , medicine , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
Increasing first-line treatment failures in low- and middle-income countries (LMICs) have led to increased use of integrase strand transfer inhibitors (INSTIs) such as dolutegravir. However, HIV-1 susceptibility to INSTIs in LMICs, especially with previous raltegravir exposure, is poorly understood due to infrequent reporting of INSTI failures and testing for INSTI drug resistance mutations (DRMs).